<unk>  is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. However, HBV signature resistance mutation M204I (a change from methionine to isoleucine at position 204 in the reverse transcriptase domain of the hepatitis B polymerase) or L180M+M204V have been associated with<unk>  resistance.<unk>  is a synthetic thymidine β-L-nucleoside analogue; it is the L-isomer of thymidine.<unk>  impairs hepatitis B virus (HBV) DNA replication by leading to chain termination. It differs from the natural nucleotide only with respect to the location of the sugar and base moieties, taking on an levorotatory configuration versus a dextrorotatory configuration as do the natural deoxynucleosides. It is taken orally in a dose of 600 mg once daily with or without food.<unk>  has no in vitro activity against HIV-1, and in a case-series of three HIV-HBV co-infected patients,<unk>  did not produce sustained HIV-1 virologic suppression or induce any resistance mutations in HIV-1. In 2016, Novartis posted a discontinuation notice for Tyzeka.
Telbivudine
Lamivudine
Sorivudine
Saquinavir
Fosamprenavir
Abacavir
Fostemsavir
Maribavir